• Profile
Close

More severe erosive phenotype despite lower circulating autoantibody levels in dipeptidyl peptidase-4 inhibitor (DPP4i)-associated bullous pemphigoid: a retrospective cohort study

American Journal of Clinical Dermatology Oct 10, 2020

Ständer S, Schmidt E, Zillikens D, et al. - Researchers conducted this retrospective cohort study to examine the clinical and immunological characteristics of patients with dipeptidyl peptidase-4 inhibitor (DPP4i)-associated bullous pemphigoid (BP) and to ascertain if there are intraclass variations between different DPP4i agents. The sample consisted of all consecutive patients diagnosed with BP throughout the years 2009–2019 in a tertiary referral center. The research comprised 273 patients with BP (mean age at diagnosis 79.1 ± 9.9 years), of whom 24 (8.8%) were linked to DPP4i. Despite lower levels of typically pathogenic antibodies, DPP4i-associated BP is characterized by a more severe blistering and erosive presentation.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay